Home > Insider Trading > Filing (0001968202-24-000025)

Filing Details

Accession Number:: 0001968202-24-000025
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-04 16:08:51
Reporting Period:: 2024-01-02

Accepted Time:: 2024-01-04 16:08:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc.	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1187443	F Arthur Ryan	777 Old Saw Mill River Road Tarrytown NY 10591		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-01-02	1	$873.91	18,446	No	4	S	Direct
Common Stock	Disposition	2024-01-02	2	$886.26	18,444	No	4	S	Direct
Common Stock	Disposition	2024-01-02	1	$887.13	18,443	No	4	S	Direct
Common Stock	Disposition	2024-01-02	1	$892.00	18,442	No	4	S	Direct
Common Stock	Disposition	2024-01-02	8	$896.47	18,434	No	4	S	Direct
Common Stock	Disposition	2024-01-02	3	$897.41	18,431	No	4	S	Direct
Common Stock	Disposition	2024-01-02	6	$898.76	18,425	No	4	S	Direct
Common Stock	Disposition	2024-01-02	14	$899.66	18,411	No	4	S	Direct
Common Stock	Disposition	2024-01-02	29	$900.59	18,382	No	4	S	Direct
Common Stock	Disposition	2024-01-02	9	$901.46	18,373	No	4	S	Direct
Common Stock	Disposition	2024-01-02	10	$902.37	18,363	No	4	S	Direct
Common Stock	Disposition	2024-01-02	13	$903.49	18,350	No	4	S	Direct
Common Stock	Disposition	2024-01-02	3	$904.49	18,347	No	4	S	Direct
Common Stock	Acquisiton	2024-01-02	135	$0.00	18,482	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Acquisiton	2024-01-02	1,607	$0.00	1,607	$888.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,607		2034-01-02	No	4	A	Direct

Footnotes

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023.
Represents volume-weighted average price of sales of 8 shares of Company stock on January 2, 2024 at prices ranging from $896.21 to $896.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $897.35 to $897.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 6 shares of Company stock on January 2, 2024 at prices ranging from $898.45 to $898.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 14 shares of Company stock on January 2, 2024 at prices ranging from $899.08 to $899.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 29 shares of Company stock on January 2, 2024 at prices ranging from $900.00 to $900.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 9 shares of Company stock on January 2, 2024 at prices ranging from $901.03 to $901.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 10 shares of Company stock on January 2, 2024 at prices ranging from $902.14 to $902.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 13 shares of Company stock on January 2, 2024 at prices ranging from $903.13 to $903.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $904.00 to $904.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price.
Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock.
On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.